Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 1/20 | 0.48 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | TYMS | P04818 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 8/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30882673 | 1.00 | CFTR (0.48) | CFTRGOPCLMNAMAPTCYP3A4 | |
| SCHEMBL9506747 | 0.88 | NPSR1 (0.58) | CFTRGOPCLMNAMAPTCYP3A4 | |
| SCHEMBL8577386 | 0.81 | SMN1; SMN2 (0.43) | CFTRGOPCLMNAMAPTCYP3A4 | |
| SCHEMBL22343694 | 0.80 | CFTR (0.48) | CFTRGOPCLMNAMAPTCYP3A4 | |
| SCHEMBL9506732 | 0.79 | SMN1; SMN2 (0.62) | CFTRGOPCLMNAMAPTCYP3A4 | |
| SCHEMBL12134500 | 0.78 | MAPT (0.47) | CFTRGOPCLMNAMAPTCYP3A4 | |
| SCHEMBL28455989 | 0.77 | NPSR1 (0.63) | CFTRGOPCLMNAMAPTCYP3A4 | |
| SCHEMBL9788150 | 0.75 | NPSR1 (0.49) | CFTRGOPCLMNAMAPTCYP3A4 | |
| SCHEMBL10745566 | 0.74 | SMN1; SMN2 (0.69) | CFTRGOPCLMNAMAPTCYP3A4 | |
| SCHEMBL11249029 | 0.74 | CFTR (0.55) | CFTRGOPCLMNAMAPTCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111295373-B | Compositions and methods for treating brain injury | 阿泽凡药物公司 | 2024-12-10 | — | — | CN | disclosed |
| US-10674699-B2 | Endophyte enhanced seedlings with increased pest tolerance | Irving Licensing Inc. (CA) | 2020-06-09 | — | — | US | disclosed |
| CN-105801588-B | A kind of narcotine derivative and its preparation method and application | 长沙凯得尔森生物技术有限公司 | 2018-09-18 | — | — | CN | disclosed |
| US-20170164621-A1 | ENDOPHYTE ENHANCED SEEDLINGS WITH INCREASED PEST TOLERANCE | Irving Licensing Inc. (CA) | 2017-06-15 | — | — | US | disclosed |
| US-9549528-B2 | Endophyte enhanced seedlings with increased pest tolerance | J.D. IRVING LIMITED (CA) | 2017-01-24 | — | — | US | disclosed |
| US-20130219569-A1 | ENDOPHYTE ENHANCED SEEDLINGS WITH INCREASED PEST TOLERANCE | J.D. IRVING LIMITED (CA) | 2013-08-22 | — | — | US | disclosed |
| US-8455395-B2 | Endophyte enhanced seedlings with increased pest tolerance | IRVING LICENSING, INC. (CA) | 2013-06-04 | — | — | US | disclosed |
| US-20110274651-A1 | Noscapine and Noscapine Analogs and Their Use in treating Infectious Diseases by Tubulin Binding Inhibition | EMORY UNIVERSITY (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110173727-A1 | Endophyte Enhanced Seedlings with Increased Pest Tolerance | J.D. IRVING, LIMITED (CA) | 2011-07-14 | — | — | US | disclosed |
| EP-2328578-A2 | NOSCAPINE AND NOSCAPINE ANALOGS AND THEIR USE IN TREATING INFECTIOUS DISEASES BY TUBULIN BINDING INHIBITION | Emory University (US) | 2011-06-08 | — | — | EP | disclosed |
| WO-2010030582-A2 | NOSCAPINE AND NOSCAPINE ANALOGS AND THEIR USE IN TREATING INFECTIOUS DISEASES BY TUBULIN BINDING INHIBITION | EMORY UNIVERSITY (US) | 2010-03-18 | — | — | WO | disclosed |
| EP-0475527-B1 | Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents | SANOFI SA (FR) | 1998-02-25 | — | — | EP | disclosed |
| US-5624922-A | Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents | STERLING WINTHROP INC. (US) | 1997-04-29 | — | — | US | disclosed |
| EP-0597540-B1 | Aryl-fused and hetaryl-fused-2,4-diazocine antiarrhythmic agents | STERLING WINTHROP INC (US) | 1996-06-05 | — | — | EP | disclosed |
| US-5380721-A | Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents | STERLING WINTHROP INC. (US) | 1995-01-10 | — | — | US | disclosed |
| EP-0597540-A1 | Aryl-fused and hetaryl-fused-2,4-diazocine antiarrhythmic agents | STERLING WINTHROP INC. (US) | 1994-05-18 | — | — | EP | disclosed |
| EP-0377406-B1 | PRESSURE-SENSITIVE OR HEAT-SENSITIVE RECORDING MATERIAL | CIBA-GEIGY AG (CH) | 1993-06-09 | — | — | EP | disclosed |
| EP-0475527-A2 | Aryl-fused and hetaryl-fused-2, 4-diazepine and 2, 4-diazocine antiarrhythmic agents | STERLING DRUG INC. (US) | 1992-03-18 | — | — | EP | disclosed |
| US-5013707-A | Pressure- or heat-sensitive recording material | CIBA-GEIGY CORPORATION (US) | 1991-05-07 | — | — | US | disclosed |
| EP-0377406-A1 | Pressure-sensitive or heat-sensitive recording material | CIBA-GEIGY AG (CH) | 1990-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110274651-A1 | Noscapine and Noscapine Analogs and Their Use in treating Infectious Diseases by Tubulin Binding Inhibition | NOS1, NOS2, TBCA | CFTR 1437/4885GOPC 653/4885LMNA 2534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.